Cite
HARVARD Citation
Xu, R. et al. (n.d.). 197TiPGLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study. Annals of oncology. p. . [Online].